These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 24684645)

  • 41. Withdrawal-related adverse events from clinical trials of clobazam in Lennox-Gastaut syndrome.
    Tolbert D; Harris SI; Bekersky I; Lee D; Isojarvi J
    Epilepsy Behav; 2014 Aug; 37():11-5. PubMed ID: 24949576
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Expanding the Treatment Landscape for Lennox-Gastaut Syndrome: Current and Future Strategies.
    Strzelczyk A; Schubert-Bast S
    CNS Drugs; 2021 Jan; 35(1):61-83. PubMed ID: 33479851
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The use of clobazam as an adjunctive treatment for Lennox-Gastaut syndrome.
    Owen RT
    Drugs Today (Barc); 2012 Nov; 48(11):697-703. PubMed ID: 23170305
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rufinamide as an adjunctive therapy for Lennox-Gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan.
    Ohtsuka Y; Yoshinaga H; Shirasaka Y; Takayama R; Takano H; Iyoda K
    Epilepsy Res; 2014 Nov; 108(9):1627-36. PubMed ID: 25219353
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clobazam for patients with Lennox-Gastaut syndrome and epilepsy.
    Seif-Eddeine H; Ng YT
    Expert Rev Neurother; 2012 Apr; 12(4):385-93. PubMed ID: 22449211
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rufinamide efficacy and safety in children aged 1-4 years with Lennox-Gastaut syndrome.
    Kim SH; Kang HC; Lee JS; Kim HD
    Brain Dev; 2018 Nov; 40(10):897-903. PubMed ID: 30166208
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Budgetary Impact of Cabazitaxel Use After Docetaxel Treatment for Metastatic Castration-Resistant Prostate Cancer.
    Flannery K; Drea E; Hudspeth L; Corman S; Gao X; Xue M; Miao R
    J Manag Care Spec Pharm; 2017 Apr; 23(4):416-426. PubMed ID: 28345444
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results.
    Laux LC; Bebin EM; Checketts D; Chez M; Flamini R; Marsh ED; Miller I; Nichol K; Park Y; Segal E; Seltzer L; Szaflarski JP; Thiele EA; Weinstock A;
    Epilepsy Res; 2019 Aug; 154():13-20. PubMed ID: 31022635
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lennox-Gastaut syndrome: a comprehensive review.
    Asadi-Pooya AA
    Neurol Sci; 2018 Mar; 39(3):403-414. PubMed ID: 29124439
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment of Lennox-Gastaut syndrome.
    Hancock EC; Cross JH
    Cochrane Database Syst Rev; 2013 Feb; 2013(2):CD003277. PubMed ID: 23450537
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Drug-drug interactions and pharmacodynamics of concomitant clobazam and cannabidiol or stiripentol in refractory seizures.
    Klein P; Tolbert D; Gidal BE
    Epilepsy Behav; 2019 Oct; 99():106459. PubMed ID: 31519475
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dosing considerations for rufinamide in patients with Lennox-Gastaut syndrome: Phase III trial results and real-world clinical data.
    Kothare S; Kluger G; Sachdeo R; Williams B; Olhaye O; Perdomo C; Bibbiani F
    Seizure; 2017 Apr; 47():25-33. PubMed ID: 28284045
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clobazam as an adjunctive therapy in treating seizures associated with Lennox-Gastaut syndrome.
    Leahy JT; Chu-Shore CJ; Fisher JL
    Neuropsychiatr Dis Treat; 2011; 7():673-81. PubMed ID: 22128252
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clobazam in the treatment of Lennox-Gastaut syndrome.
    Conry JA; Ng YT; Paolicchi JM; Kernitsky L; Mitchell WG; Ritter FJ; Collins SD; Tracy K; Kormany WN; Abdulnabi R; Riley B; Stolle J
    Epilepsia; 2009 May; 50(5):1158-66. PubMed ID: 19170737
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Assessment of treatment patterns and healthcare costs associated with probable Lennox-Gastaut syndrome.
    Piña-Garza JE; Montouris GD; Vekeman F; Cheng WY; Tuttle E; Giguere-Duval P; Duh MS; Shen V; Saurer TB; Isojarvi J
    Epilepsy Behav; 2017 Aug; 73():46-50. PubMed ID: 28609734
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials.
    Gunning B; Mazurkiewicz-Bełdzińska M; Chin RFM; Bhathal H; Nortvedt C; Dunayevich E; Checketts D
    Acta Neurol Scand; 2021 Feb; 143(2):154-163. PubMed ID: 32969022
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes.
    Chen JW; Borgelt LM; Blackmer AB
    Ann Pharmacother; 2019 Jun; 53(6):603-611. PubMed ID: 30616356
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The impact of seizure frequency on quality of life in patients with Lennox-Gastaut syndrome or Dravet syndrome.
    Auvin S; Damera V; Martin M; Holland R; Simontacchi K; Saich A
    Epilepsy Behav; 2021 Oct; 123():108239. PubMed ID: 34375802
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lennox-Gastaut syndrome. Management update.
    Al-Banji MH; Zahr DK; Jan MM
    Neurosciences (Riyadh); 2015 Jul; 20(3):207-12. PubMed ID: 26166587
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and tolerability of add-on lacosamide in children with Lennox-Gastaut syndrome.
    Grosso S; Coppola G; Cusmai R; Parisi P; Spalice A; Foligno S; Verrotti A; Balestri P
    Acta Neurol Scand; 2014 Jun; 129(6):420-4. PubMed ID: 24479878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.